Barclays
IMUX icon

Barclays’s Immunic IMUX Stock Holding History

Barclays’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-666
Closed -$73K – 7113
2018
Q3 		$73K Buy
+666
New +$1.74M ﹤0.01% 5814
2015
Q3 		– Sell
-22
Closed -$183K – 6935
2015
Q2 		$183K Buy
+22
New +$210K ﹤0.01% 4200

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Barclays's IMUX Position: Q2 2026 in Review

Barclays increased its Immunic (IMUX) stake by 103% in Q2 2026, buying an estimated $3.1K and bringing the position to 494 shares worth $7.59K. The position accounts for ﹤0.01% of the portfolio, ranked #4733.

Barclays first reported a position in IMUX in Q2 2014 and has held it in 32 quarters since. The position peaked at $217K in Q4 2021. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • Barclays held 494 shares of Immunic worth $7.59K as of Q2 2026.
  • Barclays bought 251 Immunic shares in Q2 2026, an estimated $3.1K.
  • Immunic made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4733 holding.
  • Barclays first reported a position in Immunic in Q2 2014 and has held it in 32 quarters since.
  • Barclays's Immunic position peaked at $217K in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.